Siwa Therapeutics
  • Home
  • Leadership
  • Science
    • Senescence
    • Diseases
  • Data
    • SIWA 318
    • Data
    • Other Products
  • Media
    • News
    • Videos
  • Partners
  • Contact

Month: September 2020

Home / 2020 / September
20Sep 2020 by Andrew Premovich

In The News: BIOSPACE

Uncategorized
Biospace.com has posted an article detailing our efforts to combat COVID-19. Read more here: https://www.biospace.com/article/chicago-biotech-company-testing-its-monoclonal-antibody-to-treat-covid-19/  
Read More

Recent Posts

  • In The News: Supertrends
  • Press Release: SIWA Therapeutics Grows Leadership Team with Appointment of Gabriela Rossi, Ph.D.
  • In The News: Startup.info Interview
  • In The News: BIOSPACE
  • In The News: 1000 Longevity Leaders

Archives

  • October 2020
  • September 2020
  • June 2020
  • May 2020
  • March 2020
  • February 2020
  • September 2019
  • March 2019
  • April 2018
  • January 2018
  • June 2017
  • May 2017
  • October 2016

Categories

  • Events
  • In The News
  • News
  • Press Releases
  • Uncategorized

About Us

SIWA Therapeutics, Inc. is a pre-clinical stage company with a first-in-class humanized monoclonal antibody, SIWA 318H, that selectively targets both senescent cells and cancer cells.

Recent News

  • In The News: Supertrends
  • Press Release: SIWA Therapeutics Grows Leadership Team with Appointment of Gabriela Rossi, Ph.D.
  • In The News: Startup.info Interview

JOIN OUR MAILING LIST

Navigation

  • Home
  • Leadership
  • Science
    • Senescence
    • Diseases
  • Data
    • SIWA 318
    • Data
    • Other Products
  • Media
    • News
    • Videos
  • Partners
  • Contact